Krazati (Adagrasib) Patent Expiration, LOE Window & CMS Spending
Krazati (Adagrasib) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2041-09-10 (last listed 2043-08-21), 0 AB generics, $80.7M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bristol Myers Squibb |
| FDA Application & Pathway | N216340 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2041-09-10 |
| Last Listed Patent or Exclusivity Date | 2043-08-21 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $80.7M |
| 2024 Medicare Part D Spend | $69.7M |
| 2024 Medicaid Spend | $11.0M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.